News

Rentschler Doubles Manufacturing Capacity to Address Growing Demand for Biopharmaceuticals

Rentschler Biotechnologie GmbH, a leading contract development and manufacturing organization (CDMO) for biopharmaceuticals, today announced the opening of a new facility with an capacity of two times 3,000 liters at the company’s site in Laupheim. This innovative Twin system consists of two stainless steel bioreactors for the manufacturing of cell culture-derived proteins and is complemented by directly connected equipment for protein purification. The system increases Rentschler’s manufacturing capacity for the second time within a year; a new 2,000 liter single-use…

BioProcess International Announces Finalists for the 2016 BioProcess International Awards

BioProcess International (BPI), the biopharmaceutical industry’s leading business-to-business publication, today announced the finalists for the 2016 BioProcess International Awards. The awards celebrate the outstanding individual and team achievements, recognize emerging companies and their technologies, highlight groundbreaking business collaborations and strategies, corporate responsibility and technology applications that will allow the industry to deliver better, more effective treatments to a global patient base. Award winners and finalists, individually voted on and ranked by the 2016 BPI Awards Judging committee from 125+ nominations…

Merck KGaA, Darmstadt, Germany, Joins DiViNe Consortium to Address Low Yields, High Costs of Vaccine Purification Processes

Merck KGaA, Darmstadt, Germany, a leading science and technology company, has joined theDiViNe project, a European consortium of six companies to address the biggest challenges facing the development, manufacture and delivery of vaccines. The objective of the DiViNe project is to create an integrated, cost-effective purification program specifically tailored for vaccines that achieves higher yields while preserving product integrity. Merck KGaA, Darmstadt, Germany’s specific focus will be on simplifying the process of vaccine purification that typically relies on affinity chromatography,…

Qosina Introduces New Barbed Check Valves

Qosina is pleased to announce the addition of eight new barbed check valves to complement their extensive line of stock components. Available in three different configurations, these barbed valves have a low, 0.087 psi cracking pressure.  The barb to barb straight and reducing configurations (#80500 – #80503) accommodate 1/8 inch (0.125 inch, 3.2 mm) and 3/32 inch (0.093 inch, 2.4 mm) ID tubes and are made of MABS and silicone.  The female luer lock to barb and the barb to…

Lonza to Offer Novel Anc-AAV Gene Therapy Technology Through Exclusive Licensing Agreement with Massachusetts Eye and Ear®

Lonza Houston, Inc., a global leader in viral gene and cell therapy manufacturing, and Massachusetts Eye and Ear®, the world’s largest vision and hearing research center, have entered into a strategic agreement that provides customers the ability to in-license Anc80 and other Anc-AAVs for the clinical development and commercialization of novel gene therapies. The agreement is designed to accelerate gene therapy drug development across the field in order to address diseases in need of treatments and thereby ultimately reach more…

Distek, Inc. Releases Opt-Diss 410 In-Situ UV Fiber Optic System for Dissolution Testing

Distek, Inc., a leading manufacturer of laboratory testing instruments for the pharmaceutical and biotechnology industry, as well as an experienced provider of validation and qualification services, announced today the release of the Opt-Diss 410 next generation in-situ UV fiber optic system for dissolution testing. No more sampling! The Distek Opt-Diss 410 UV fiber optic system for dissolution testing measures directly in the vessel, eliminating problematic filters, tubing and pumps used in conventional sampling. Patented ARCH probes designed specifically for dissolution…

MilliporeSigma Launches New Gene Editing Technology to Engineer Virus Resistant CHO Cell Lines

MilliporeSigma today launched a first-of-its-kind gene editing technology to modify CHO cell lines to be resistant to minute virus of mice (MVM), a common contamination threat that remains despite the shift to chemically-defined, animal component-free manufacturing processes. CHO cells are commonly used in the manufacture of biologics. MilliporeSigma’s new Centinel™ technology targets genes which play a role in MVM susceptibility. Viral contaminations like MVM can have major consequences for biopharmaceutical manufacturers, costing hundreds of millions of dollars, according to industry…

Lonza Releases Second-Generation Immunogenicity Assessment and Optimization Platform for Development of Therapeutic Proteins, Vaccines and Cell Therapies

Lonza, a global leader in biological development and manufacturing, announced today the release of its second-generation immunogenicity assessment platform. The upgraded platform consists of state-of-the-art in silico and in vitro/ex vivo technologies to evaluate immunogenicity risk during the pre-clinical development of therapeutic proteins. In the context of vaccine and cell therapy development, the platform enables the rational design and testing of optimal immune responses in healthy donor or patient populations. This second-generation platform provides a comprehensive toolbox to assess customers’…

S-Bio Launches EZGlyco mAB Kit with 2-AB for N Glycan Sample Preparation from IgG in cell culture for HPLC analysis

S-BIO1 has launched today EZGlyco™ mAb-N Kit with 2-AB, a breakthrough new product that enables scientists to analyze N -glycans in IgG and Fc-fusion proteins from culture supernatant samples in a rapid, simplified and streamlined single tube operation. The kit is a valuable tool supporting customers in glycoprotein characterization for biotherapeutic development. Therapeutic monoclonal antibodies (IgG, mAb) are routinely expressed in recombinant expression systems. N-glycosylation is one of the most important post-translational modifications. Monitoring of glycosylation in antibody development and…

Sartorius Stedim Biotech Presents the First Fully Integrated Upstream Platform

Sartorius Stedim Biotech (SSB), an international leading supplier for the biopharmaceutical industry, has developed an innovative and fully integrated technology platform to meet the requirements of today’s upstream bioprocessing. It combines a top-performing expression system with outstanding equipment and process control for the rapid development and scale-up of robust, high-titer commercial manufacturing processes. The biopharmaceutical industry is facing a series of challenges that it must address in order for it to deliver safe and efficacious products to a market made…